Clinical Resource Center

The KRYSTEXXA Connect Clinical Resource Center contains information and tools to help you effectively prepare and administer KRYSTEXXA® (pegloticase) Injection, 8 mg/mL, for Intravenous Infusion. You will also find useful information to help educate your patients about KRYSTEXXA.

Materials for You

These useful resources provide guidance on how to properly prepare and administer KRYSTEXXA (pegloticase) injection:

Preparation and
Administration Card


preparation-administration-card

An overview of key steps, including storage information.

Infusion Checklists


infusion-checklists

Helpful reminder of the steps and precautions necessary for the administration of KRYSTEXXA.

Patient Counseling
Guide


patient-counseling-guide-icon

Discussion points for your conversations with patients about KRYSTEXXA.

Materials for Your Patient

These materials can help you educate and guide your patients:

Medication Guide


medication-guide

Before each infusion, the Medication Guide should be given to and discussed with each patient. The Medication Guide can be used to educate patients about what they need to know and do when receiving KRYSTEXXA therapy.

Patient Instructions


patient-instructions

Key reminders for patients about their KRYSTEXXA treatment plan.

If you have questions regarding treatment with KRYSTEXXA, please contact the KRYSTEXXA Connect Hotline at 1-888-KRYSTEXXA (1-888-579-7839) Monday through Friday from 8:00 AM to 8:00 PM ET. Staff members can connect you with your local KRYSTEXXA representative or Horizon Pharma Rheumatology Medical Information.

IMPORTANT SAFETY INFORMATION

INDICATION

KRYSTEXXA® (pegloticase) is a PEGylated uric acid–specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy.

Gout refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.

Important Limitations of Use:

KRYSTEXXA is not recommended for the treatment of asymptomatic hyperuricemia.

WARNING: ANAPHYLAXIS AND INFUSION REACTIONS
  • Anaphylaxis and infusion reactions have been reported to occur during and after administration of KRYSTEXXA.
  • Anaphylaxis may occur with any infusion, including a first infusion, and generally manifests within 2 hours of the infusion. However, delayed-type hypersensitivity reactions have also been reported.
  • KRYSTEXXA should be administered in healthcare settings and by healthcare providers prepared to manage anaphylaxis and infusion reactions.
  • Patients should be premedicated with antihistamines and corticosteroids.
  • Patients should be closely monitored for an appropriate period of time for anaphylaxis after administration of KRYSTEXXA.
  • Monitor serum uric acid levels prior to infusions and consider discontinuing treatment if levels increase to above 6 mg/dL, particularly when 2 consecutive levels above 6 mg/dL are observed.
CONTRAINDICATIONS
  • Glucose-6-phosphate dehydrogenase (G6PD) Deficiency: Before starting KRYSTEXXA, confirm patients are not G6PD deficient. Patients at higher risk for G6PD deficiency (e.g., those of African and Mediterranean ancestry) should be screened because of the risk of hemolysis and methemoglobinemia, however any patient could be affected.
WARNINGS AND PRECAUTIONS
  • Anaphylaxis: Anaphylaxis occurred in patients treated with KRYSTEXXA. Anaphylaxis may occur with any infusion, including a first infusion, and generally manifests within 2 hours of the infusion. However, delayed-type hypersensitivity reactions have also been reported. KRYSTEXXA should be administered in healthcare settings and by healthcare providers prepared to manage anaphylaxis. Patients should be premedicated with antihistamines and corticosteroids. Patients should be closely monitored for an appropriate period of time for anaphylaxis after administration of KRYSTEXXA.
  • Infusion Reactions: Infusion reactions occurred in patients treated with KRYSTEXXA. KRYSTEXXA should be administered in a healthcare setting and by healthcare providers prepared to manage infusion reactions. Patients should be premedicated with antihistamines and corticosteroids. Monitor patients closely for signs and symptoms of infusion reactions. In the event of an infusion reaction, the infusion should be slowed, or stopped and restarted at a slower rate. If a severe infusion reaction occurs, discontinue infusion and institute treatment as needed. The risk of an infusion reaction is higher in patients who have lost therapeutic response.
    • Monitor serum uric acid levels prior to infusions and consider discontinuing treatment if levels increase to above 6 mg/dL, particularly when 2 consecutive levels above 6 mg/dL are observed.
    • Concomitant use of KRYSTEXXA and oral urate-lowering agents may blunt the rise of serum uric acid levels. It is recommended that patients discontinue oral urate-lowering agents and not institute therapy with oral urate-lowering agents while taking KRYSTEXXA.
  • Gout Flares: An increase in gout flares is frequently observed upon initiation of antihyperuricemic therapy, including treatment with KRYSTEXXA. If a gout flare occurs during treatment, KRYSTEXXA need not be discontinued. Gout flare prophylaxis with a nonsteroidal anti-inflammatory drug (NSAID) or colchicine is recommended starting at least 1 week before initiation of KRYSTEXXA therapy and lasting at least 6 months, unless medically contraindicated or not tolerated.
  • Congestive Heart Failure: KRYSTEXXA has not been formally studied in patients with congestive heart failure, but some patients in clinical trials experienced exacerbation. Exercise caution when using KRYSTEXXA in patients who have congestive heart failure, and monitor patients closely following infusion.
  • Re-treatment: No controlled clinical data is available on the safety and efficacy of re-treatment with KRYSTEXXA after stopping treatment for longer than 4 weeks. Patients receiving re-treatment may be at increased risk for anaphylaxis and infusion reactions and should be monitored carefully.
ADVERSE REACTIONS

The most commonly reported serious adverse reactions in the pivotal trial with the approved regimen of 8 mg KRYSTEXXA administered every 2 weeks were gout flares, infusion reactions, and anaphylaxis. Most common adverse reactions: gout flares (77%), infusion reactions (26%), nausea (12%), contusion or ecchymosis (11%), nasopharyngitis (7%), constipation (6%), chest pain (6%), anaphylaxis (5%), and vomiting (5%). In addition to events occurring in greater than 5%, exacerbation of pre-existing congestive heart failure occurred in 2%.

Please see the Medication Guide and Prescribing Information, including Boxed Warning, for more information.

To report SUSPECTED ADVERSE REACTIONS, contact Horizon Pharma plc at 1-866-479-6742, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.